Dylan Dupuis
Stock Analyst at Roth MKM
(3.20)
# 2,017
Out of 4,851 analysts
9
Total ratings
100%
Success rate
129.31%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dylan Dupuis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMMB Chemomab Therapeutics | Reinstates: Buy | $7 | $1.35 | +420.14% | 2 | Dec 19, 2023 | |
| IVA Inventiva | Reiterates: Buy | $11 | $3.38 | +225.44% | 2 | Sep 21, 2023 | |
| TERN Terns Pharmaceuticals | Reiterates: Buy | $23 | $3.51 | +555.27% | 3 | Aug 8, 2023 | |
| VKTX Viking Therapeutics | Assumes: Buy | $32 | $27.00 | +18.52% | 1 | May 31, 2023 | |
| UBX Unity Biotechnology | Initiates: Buy | $10 | $0.72 | +1,284.27% | 1 | May 31, 2023 |
Chemomab Therapeutics
Dec 19, 2023
Reinstates: Buy
Price Target: $7
Current: $1.35
Upside: +420.14%
Inventiva
Sep 21, 2023
Reiterates: Buy
Price Target: $11
Current: $3.38
Upside: +225.44%
Terns Pharmaceuticals
Aug 8, 2023
Reiterates: Buy
Price Target: $23
Current: $3.51
Upside: +555.27%
Viking Therapeutics
May 31, 2023
Assumes: Buy
Price Target: $32
Current: $27.00
Upside: +18.52%
Unity Biotechnology
May 31, 2023
Initiates: Buy
Price Target: $10
Current: $0.72
Upside: +1,284.27%